Neurocrine Biosciences, Inc.
MX ˙ BMV ˙ US64125C1099
SecurityMX:NBIX / Neurocrine Biosciences, Inc.
InstitutionCIBC Asset Management Inc
Latest Disclosed Ownership5,544 shares
Latest Disclosed Value $ 730,367
CIBC Asset Management Inc reports 25.34% increase in ownership of NBIX / Neurocrine Biosciences, Inc.

On May 12, 2026 - CIBC Asset Management Inc filed a 13F-HR form disclosing ownership of 5,544 shares of Neurocrine Biosciences, Inc. (MX:NBIX) valued at $730,367 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 10, 2026 disclosing 4,423 shares of Neurocrine Biosciences, Inc.. This represents a change in shares of 25.34% during the quarter.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-12 2026-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 5,544 1,121 25.34 730 16.43 0.0018
2026-02-10 2025-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 4,423 1,290 41.17 627 42.82 0.0015
2025-10-31 2025-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 3,133 0 0.00 440 11.70 0.0013
2025-08-14 2025-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 3,133 -1,155 -26.94 394 -17.09 0.0012
2025-05-13 2025-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 4,288 210 5.15 474 -14.75 0.0016
2025-01-31 2024-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 4,078 487 13.56 557 34.62 0.0018
2024-11-06 2024-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 3,591 191 5.62 414 -11.75 0.0013
2024-08-01 2024-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 3,400 153 4.71 468 4.70 0.0017
2024-05-09 2024-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 3,247 7 0.22 448 4.93 0.0016
2024-02-13 2023-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 3,240 -229 -6.60 427 9.23 0.0016
2023-10-30 2023-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 3,469 48 1.40 390 21.12 0.0016
2023-08-14 2023-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 3,421 3 0.09 323 -6.67 0.0012
2023-05-12 2023-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 3,418 325 10.51 346 -6.50 0.0014
2023-02-13 2022-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 3,093 -1,163 -27.33 369 -18.36 0.0016
2022-11-03 2022-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 4,256 12 0.28 452 9.18 0.0020
2022-08-09 2022-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 4,244 -59 -1.37 414 2.73 0.0017
2022-05-06 2022-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 4,303 24 0.56 403 10.71 0.0014
2022-02-08 2021-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 4,279 423 10.97 364 -1.62 0.0013
2021-11-09 2021-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 3,856 338 9.61 370 8.19 0.0015
2021-08-16 2021-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 3,518 6 0.17 342 0.00 0.0014
2021-05-14 2021-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 3,512 -10,734 -75.35 342 -74.95 0.0015
2021-02-03 2020-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 14,246 818 6.09 1,365 5.73 0.0064
2020-11-05 2020-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 13,428 10,053 297.87 1,291 213.35 0.0066
2020-07-28 2020-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 3,375 0 0.00 412 41.10 0.0024
2020-04-30 2020-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 3,375 0 0.00 292 -19.56 0.0021
2020-02-14 2019-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 3,375 194 6.10 363 26.48 0.0021
2019-10-30 2019-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 3,181 0 0.00 287 6.69 0.0017
2019-08-05 2019-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 3,181 0 0.00 269 -3.93 0.0016
2019-05-06 2019-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 3,181 0 0.00 280 23.35 0.0017
2019-02-12 2018-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 3,181 0 0.00 227 -41.94 0.0017
2018-11-02 2018-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 3,181 0 0.00 391 24.92 0.0024
2018-08-09 2018-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 3,181 215 7.25 313 27.24 0.0020
2018-04-30 2018-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 2,966 0 0.00 246 6.96 0.0016
2018-02-02 2017-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 2,966 2,966 230 0.0014
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.